Tag: Biogens
Biogen’s lagging Vumerity, stalled by the pandemic, faces ‘critical’ stretch ahead,...
Biogen’s Tecfidera follow-up Vumerity hit the market late last year, but eight months into the launch, the new multiple sclerosis drug is yet to meaningfully take off.
The drug...
Judge wipes out Biogen’s Tecfidera patent protections in suit against Mylan
In the high-stakes patent fight between Biogen and Mylan over Tecfidera’s only remaining patent, Mylan has scored a major win in federal court.
U.S. District...
Biogen’s new Spinraza data for earlier use ‘pretty amazing,’ analyst says
Biogen’s spinal muscular atrophy med Spinraza hit the market running after its launch, helping fuel growth at the drugmaker as its MS franchise faced...